Product
TG-1701
1 clinical trial
2 indications
Indication
Non-Hodgkin LymphomaIndication
Chronic Lymphocytic LeukemiaClinical trial
A Phase 1 Pharmacokinetic and Pharmacodynamic Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell MalignanciesStatus: Active (not recruiting), Estimated PCD: 2024-06-01